Compounds > l 35
Page last updated: 2024-12-08

l 35

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 35: a negative effector of hemoglobin; RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID195347
CHEMBL ID76029
SCHEMBL ID1306107
MeSH IDM0176648

Synonyms (25)

Synonym
CHEMBL76029
L35 ,
2-[4-({[(3,5-dichlorophenyl)amino]carbonyl}amino)phenoxy]-2-methylpropanoic acid
l 35
DB08077
121809-80-1
2-(4-{[(3,5-dichlorophenyl)carbamoyl]amino}phenoxy)-2-methylpropanoic acid
2-[4-[(3,5-dichlorophenyl)carbamoylamino]phenoxy]-2-methylpropanoic acid
SCHEMBL1306107
l-35
ps3uc84iqa ,
unii-ps3uc84iqa
2-(4-(3,5-dichlorophenylureido)phenoxy)-2-methylpropionic acid
2-(4-(3,5- dichlorophenylureido)phenoxy)-2-methyl-propionic acid
OYJPTSMWFKGZJM-UHFFFAOYSA-N ,
2-(4-(3,5-dichlorophenylureido)phenoxy)-2-methyl-propionic acid
DTXSID70153370
2-[4-(3,5-dichlorophenylureido)phenoxy]-2-methylpropionic acid
Q27097308
propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-
propanoic acid, 2-(4-((((3,5-dichlorophenyl)amino)carbonyl)amino)phenoxy)-2-methyl-
2-(4-((((3,5-dichlorophenyl)amino)carbonyl)amino)phenoxy)-2-methylpropanoic acid
2-(4-((3,5-dichlorophenyl)carbamoylamino)phenoxy)-2-methylpropanoic acid
PD004809
AKOS040752297
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID231976Ratio of effect of compound on affinity of hemoglobin for oxygen to that of control1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226490Oxygen pressure in mmHg at which the control hemoglobin solution (in presence of 10 mM compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID221788Ability of 0.2 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226489Oxygen pressure in mmHg at which the control hemoglobin solution (no compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID221789Ability of 0.5 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226496Dose-response study in whole blood at a concentration of 4.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226493Dose-response study in whole blood at a concentration of 1.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226495Dose-response study in whole blood at a concentration of 2.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID93011Ability of 0.5 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226492Dose-response study in whole blood at a concentration of 0.5 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226491Allosteric activity evaluated as the ratio of the oxygen pressure in mmHg between hemoglobin-compound and compound-free hemoglobin (control) solution at which 50% oxygen saturation's are respectively attained.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors.
AID226494Dose-response study in whole blood at a concentration of 10.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID92893Ability of 0.2 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (25.00)18.7374
1990's3 (18.75)18.2507
2000's4 (25.00)29.6817
2010's3 (18.75)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.61 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbon monoxide
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.		2.4420carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.420halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
glycine
[no description available]		1.9410alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
phytic acid
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.		2.0610inositol phosphate
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		1.9410L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		1.9310amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
potassium sulfate
potassium sulfate: RN given refers to cpd with MF of K2-H2SO4		1.9410inorganic potassium salt;
potassium salt
bezafibrate
[no description available]		2.940aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
1,3,6,8-pyrene tetrasulfonate
1,3,6,8-pyrene tetrasulfonate: RN given refers to parent cpd		2.0210
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		1.9310iditolfungal metabolite
efaproxiral
efaproxiral: RN & structure given in first source; allosteric effector of hemoglobin		1.9710
l 345
L 345: RN & structure given in first source		2.8940
rsr 4
4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid): allosteric effector of hemoglobin; structure given in first source		2.3820
serine o-sulfate
serine O-sulfate: RN given refers to (L)-isomer. L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine.		1.9410L-serine derivative;
non-proteinogenic L-alpha-amino acid;
O-sulfoamino acid
cortisone
[no description available]		1.931011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
tyrosine o-sulfate
O(4')-sulfo-L-tyrosine : An O-sulfoamino acid that is L-tyrosine in which the phenolic hydrogen has been replaced by a sulfo group.		1.9310aryl sulfate;
L-tyrosine derivative;
O-sulfoamino acid		human metabolite
methylthiouracil
Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism.		1.9310pyrimidone
cystine
[no description available]		1.9310
lr 16
LR 16: structure given in first source; has potent effects on oxygen affinity of hemoglobin, on blood cholesterol and on low density lipoprotein		2.8940
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.610
fibrinopeptide b
Fibrinopeptide B: Two small peptide chains removed from the N-terminal segment of the beta chains of fibrinogen by the action of thrombin. Each peptide chain contains 20 amino acid residues. The removal of fibrinopeptides B is not required for coagulation.		1.9310
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes
[description not available]		01.9310